ImmVira, a biotech startup based in China, has announced the appointment of Dr Oliver Kong as Chief Medical Officer (CMO). Dr Kong will be fully in charge of global clinical development and international collaboration of company pipelines, and participate in overall corporate strategy planning and implementation.
Dr Kong has more than 25 years of experience in the pharmaceutical industry in clinical development and medical affairs in various diseases or treatment fields such as oncology, autoimmune diseases and infectious diseases. Before joining ImmVira, he served as Chief Medical Officer and Corporate Vice President at Qilu Pharmaceuticals, Vice President of Clinical Oncology at Hengrui Therapeutics, Senior Global Medical Leader of Global Medical Affairs at Novartis Oncology, Senior Medical Director at Celegene and Medical Director of US Medical Affairs at Bayer HealthCare Pharmaceuticals.
Providing more effective and safe cancer treatment solutions for global patients has always been Dr Kong's motivation. According to him, oncolytic virotherapy has great potential to further meet urgent unmet medical needs.
